SynAct Pharma's Board of Directors and management sign subscription commitment for warrant exercise of series TO 2
SynAct Pharma AB ("SynAct") today announces that the company's Board of Directors and management have agreed to subscribe for 100 percent of the Board of Directors and management's total holding of warrants of series TO 2 ("TO 2"). In total, the Board of Directors and management have agreed on a subscription of approximately SEK 1.2 million of TO 2 ahead of the exercise period that will run between1 July – 22 July, 2020.Warrants of series TO 2 in brief In October 2019, SynAct completed a directed issue and a rights issue were 4 891 268 warrants of series TO 2 were issued. During the